Technical analysis of Ensysce Biosciences, Inc. (ENSC): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.
Price Performance
| 1 month | +16.31% |
| 3 months | +65.06% |
| Year-to-date | -51.33% |
| 1 year | -78.68% |
| 3 years | -98.26% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $2.75 |
| 52-week Low | $0.23 |
| Avg Volume (90d) | 11.5M |
Technical Indicators
| SMA 50 | $0.37 |
| SMA 200 | $0.56 |
| 30-day Volatility (annualised) | 150.9% |
| Price vs SMA 50 | +22.5% |
| Price vs SMA 200 | -19.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.18 | |
| 2025-11 | $1.77 | -18.8% |
| 2025-12 | $0.92 | -48.0% |
| 2026-01 | $0.73 | -21.1% |
| 2026-02 | $0.62 | -14.2% |
| 2026-03 | $0.54 | -13.6% |
| 2026-04 | $0.37 | -31.0% |
| 2026-05 | $0.28 | -24.4% |
| 2026-06 | $0.29 | +3.2% |
| 2026-07 | $0.25 | -12.8% |
| 2026-08 | $0.39 | +55.2% |
| 2026-09 | $0.45 | +14.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $0.45 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -7.69 |
| EV / EBITDA | 0.16 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.25 |
| Current Ratio | 0.70 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -29.36 |